European Medicines Agency (EMA) | What's new 日本語 フォロー Orphan drug designation: 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib) for the treatment of medullary thyroid carcinoma, 19/02/2021 Withdrawn Orphan designation: 2-[6-(6,7-Dimethoxyquinolin-3-yl)pyridin-3-yl]-N-[3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-5-yl]acetamide (zeteletinib) Treatment of medullary thyroid carcinoma, 19/02/2021 Withdrawn ema.europa.eu
